Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patientsReport as inadecuate




Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients - Download this document for free, or read online. Document in PDF available to download.

Journal of Pharmaceutical Health Care and Sciences

, 1:28

First Online: 06 October 2015Received: 08 May 2015Accepted: 21 September 2015DOI: 10.1186-s40780-015-0028-1

Cite this article as: Mitsuboshi, S., Yamada, H., Nagai, K. et al. J Pharm Health Care Sci 2015 1: 28. doi:10.1186-s40780-015-0028-1

Abstract

BackgroundFebuxostat is a novel xanthine oxidase inhibitor. However, few studies have examined the long-term efficacy and tolerability of febuxostat after switching from allopurinol in hemodialysis HD patients. Therefore, the present study evaluated the long-term efficacy and tolerability of febuxostat in HD patients after switching from allopurinol.

FindingsWe monitored the levels of hemoglobin, hematocrit, platelet count, blood urea nitrogen, serum creatinine, serum sodium, serum potassium, serum chloride, serum calcium, serum inorganic phosphorus, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, and total protein that were considered overall as a tolerability index, while the serum uric acid UA level was considered an index of efficacy. All values were measured at baseline and at 1, 6, 12, and 16 months after the switch to febuxostat therapy. All subjects switched from allopurinol 100 mg-day to febuxostat 10 mg-day in August 2013. Clinical laboratory data were collected at baseline in July 2013 until December 2014. Nine patients were included in the study analysis. Results showed that clinical laboratory data at baseline versus those at 16 months were not significantly different. Serum UA levels, which represented the efficacy index, were significantly different between the baseline level 6.8 ± 1.4 and those at 1, 6, 12, and 16 months 5.2 ± 1.1, 5.1 ± 1.1, 4.6 ± 0.9, and 5.4 ± 1.8 mg-dL, respectively; all p < 0.05.

ConclusionSwitching from allopurinol to febuxostat in HD patients reduced serum UA levels, with no changes in other clinical laboratory data in the long term.

KeywordsFebuxostat Allopurinol Hemodialysis Uric acid AbbreviationsCKDchronic kidney disease

CVDcardiovascular disease

HDhemodialysis

XOxanthine oxidase

UAuric acid

Download fulltext PDF



Author: Satoru Mitsuboshi - Hitoshi Yamada - Kazuhiko Nagai - Hideo Okajima

Source: https://link.springer.com/







Related documents